---
title: "Duality Biotherapeutics plans share buyback of up to US$40 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286927981.md"
description: "Duality Biotherapeutics has announced a share buyback plan of up to USD 40 million, funded from internal resources, with shares to be held as treasury stock. Chairman and CEO Zhu Zhongyuan will also purchase up to USD 5 million in shares using personal funds. The announcement was made on May 19, 2026."
datetime: "2026-05-19T14:09:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286927981.md)
  - [en](https://longbridge.com/en/news/286927981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286927981.md)
---

# Duality Biotherapeutics plans share buyback of up to US$40 million

-   Duality Biotherapeutics set a share buyback plan of up to USD 40 million under its existing repurchase mandate, with open-market purchases to be timed at its discretion. \* Repurchases will be funded from internal resources, with shares to be held as treasury stock. \* Chairman and CEO Zhu Zhongyuan also plans to buy up to USD 5 million of shares in the open market using personal funds. \* The announcement was dated May 19, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260519-12164360), on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [09606.HK](https://longbridge.com/en/quote/09606.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis](https://longbridge.com/en/news/286903126.md)
- [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Sutro Biopharma Q1 revenue beats analyst expectations](https://longbridge.com/en/news/286462966.md)
- [RenovoRx (RNXT) Q1 2026 Earnings Transcript](https://longbridge.com/en/news/286914537.md)